Neurol India Home 
 

REVIEW ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 2  |  Page : 284--293

Brivaracetam: How Well Does It Fare as an Anti-Epileptic? A Review

Madhuri Khilari1, Pradeep P Nair2, Brajesh Kumar Jha3 
1 Consultant Neurologist, Apollo Health City, Jubilee Hills, Hyderabad, Telangana, India
2 Department of Neurology, JIPMER, Puducherry, India
3 Lead – Scientific writing, Indegene Pvt Ltd., Nagwara, Bangalore, India

Correspondence Address:
Dr. Madhuri Khilari
Consultant Neurologist, Apollo Health City, Jubilee Hills, Hyderabad, Telangana
India
Dr. Pradeep P Nair
HOD, Department of Neurology, JIPMER, Super-Specialty Block, Pondicherry - 605 006
India

Objectives: Epilepsy is a common neurological ailment contributing to significant disability. About one-third of all epilepsy patients would be refractory to two or more medications. Brivaracetam (BRV) is one of the newer anti-seizure medications on which extensive data is available, but its efficacy as an early add-on agent (first/second adjuvant) is unclear. The principal objective of this review is to assess the efficacy of BRV as an early add-on agent in refractory Focal Onset Seizures (FOS) and its pharmacology and usage in various clinical situations associated with seizures. Methods: We searched two databases, Medline and Cochrane Central, for papers on BRV and FOS, and selected six studies with randomized parallel control design to extract the data for a meta-analysis. We also did a comprehensive review of the available literature on its pharmacology and usage in various clinical scenarios associated with seizures. Results: For the meta-analysis, we extracted 145 articles; six studies fulfilled the selection criteria that gave us data on 1938 patients who received Brivaracetam as an early add-on agent in FOS. The Risk Ratio (RR) (95% CI) for 50% responders across the trials was 1.88 (1.55–2.29). Similarly, the overall RR (95% CI) was 5.82 (2.15–15.70) for seizure freedom. Conclusion: Our analysis provides moderate evidence for Brivaracetam as an effective agent as an early adjuvant in FOS. Its efficacy for several other indications needs further clinical trials and evaluation.


How to cite this article:
Khilari M, Nair PP, Jha BK. Brivaracetam: How Well Does It Fare as an Anti-Epileptic? A Review.Neurol India 2021;69:284-293


How to cite this URL:
Khilari M, Nair PP, Jha BK. Brivaracetam: How Well Does It Fare as an Anti-Epileptic? A Review. Neurol India [serial online] 2021 [cited 2021 Jun 21 ];69:284-293
Available from: https://www.neurologyindia.com/article.asp?issn=0028-3886;year=2021;volume=69;issue=2;spage=284;epage=293;aulast=Khilari;type=0